Healthcare & Pharma
Pipeline value, patent cliffs, FDA approval probabilities, and blockbuster economics
In 2022, Humira generated $21.2 billion in revenue for AbbVie — roughly 37% of total company sales from a single drug. By 2024, Humira revenue had fallen to $8.
99 billion, a 58% decline in two years, as biosimilar competition flooded the U.S. market after patent exclusivity expired.
AbbVie's stock barely moved. Why? Because investors had watched AbbVie spend a decade preparing: building a 130-patent thicket to delay biosimilar entry until 2023, using that window to develop successors (Skyrizi and Rinvoq), and transitioning the revenue base so that by 2025, Humira was expected to represent only 9% of revenue.
This is the healthcare sector in miniature: the value of a pharma company is never in what it's selling today, but in what's in its pipeline, when its patents expire, and whether it has built the bridge to the other side of the cliff.
That is the opening. Finishing a lesson is where it stops being interesting and starts being useful: the full lesson runs to 6 sections and ends with 5 practice questions. A free account is what opens the rest, and the other 255 lessons in the Academy with it. No card.
What this lesson covers
- 1The patent cliff: pharma's structural lifecycle
- 2Drug revenue lifecycle: the cliff pattern
- 3Pipeline valuation: probability-weighted revenue
- 4FDA approval probability by phase and therapeutic area
- 5Blockbuster economics: why one drug can make a company
- 6AbbVie: navigating the largest patent cliff in pharma history